Skip to main content
Top
Published in: Annals of Surgical Oncology 11/2019

01-10-2019 | Metastasis | Endocrine Tumors

Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center

Authors: Elliot A. Asare, MD, MS, Angelica Silva-Figueroa, MD, Kenneth R. Hess, PhD, Naifa Busaidy, MD, Paul H. Graham, MD, Elizabeth G. Grubbs, MD, Jeffrey E. Lee, MD, Michelle D. Williams, MD, Nancy D. Perrier, MD

Published in: Annals of Surgical Oncology | Issue 11/2019

Login to get access

Abstract

Background

Development of distant metastases (DM) is associated with markedly decreased survival in parathyroid carcinoma (PC). We sought to identify factors associated with development of DM and to quantify the effect that development of DM had on overall survival (OS).

Methods

Patients with surgically resected local/regional PC treated or surveilled at a tertiary-referral cancer hospital from 1980 to 2017 were included. We assessed the association between biochemical and clinicopathologic factors (preoperative parathyroid hormone (PTH) levels, sex, race, age, preoperative serum calcium levels, serum calcium levels at 6 months postop, tumor size, and extent of resection) with the development of DM. We also assessed the effect of development of DM on OS.

Results

Seventy-five patients with PC were assessed; 17 (22.7%) developed DM at a median follow-up of 77 months. The cumulative incidence of DM in the cohort was 20, 30, and 38% at 5, 10, and 20 years respectively. Tumor size > 3.2 cm based on recursive partitioning analysis was the only significant predictor for development of DM (hazard ratio (HR) = 3.51; 95% confidence interval [CI] 1.04–11.91; p = 0.04). Median OS for the entire cohort was 17 years compared with 40 months for the cohort who developed DM. The HR for death after distant metastasis was 9.6 (95% CI 4.2–22.3; p < 0.0001).

Conclusions

Development of distant metastasis during surveillance is associated with decreased OS, including late recurrences. Primary tumor size should be considered in future interval surveillance and development of treatment algorithms.
Literature
1.
go back to reference Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109:1736–41.CrossRefPubMed Lee PK, Jarosek SL, Virnig BA, et al. Trends in the incidence and treatment of parathyroid cancer in the United States. Cancer. 2007;109:1736–41.CrossRefPubMed
2.
go back to reference Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96:3679–86.CrossRefPubMed Harari A, Waring A, Fernandez-Ranvier G, et al. Parathyroid carcinoma: a 43-year outcome and survival analysis. J Clin Endocrinol Metab. 2011;96:3679–86.CrossRefPubMed
3.
go back to reference Sandelin K, Auer G, Bondeson L, et al. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992;16:724–31.CrossRefPubMed Sandelin K, Auer G, Bondeson L, et al. Prognostic factors in parathyroid cancer: a review of 95 cases. World J Surg. 1992;16:724–31.CrossRefPubMed
4.
go back to reference Asare EA, Sturgeon C, Winchester DJ, et al. Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann Surg Oncol. 2015;22:3990-5.CrossRefPubMed Asare EA, Sturgeon C, Winchester DJ, et al. Parathyroid carcinoma: an update on treatment outcomes and prognostic factors from the National Cancer Data Base (NCDB). Ann Surg Oncol. 2015;22:3990-5.CrossRefPubMed
5.
go back to reference Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26:716–26.CrossRefPubMed Busaidy NL, Jimenez C, Habra MA, et al. Parathyroid carcinoma: a 22-year experience. Head Neck. 2004;26:716–26.CrossRefPubMed
6.
go back to reference DeLellis R, Heitz PU. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004. DeLellis R, Heitz PU. Pathology and genetics of tumours of endocrine organs. Lyon: IARC Press; 2004.
7.
go back to reference Silva-Figueroa AM, Hess KR, Williams MD, et al. Prognostic scoring system to risk stratify parathyroid carcinoma. J Am Coll Surg. 2017;224:980–7.CrossRef Silva-Figueroa AM, Hess KR, Williams MD, et al. Prognostic scoring system to risk stratify parathyroid carcinoma. J Am Coll Surg. 2017;224:980–7.CrossRef
8.
go back to reference Zhang H, Singer B. Recursive partitioning in the health sciences. New York: Springer; 1999.CrossRef Zhang H, Singer B. Recursive partitioning in the health sciences. New York: Springer; 1999.CrossRef
9.
10.
go back to reference Xue S, Chen H, Lv C, et al. Preoperative diagnosis and prognosis in 40 parathyroid carcinoma patients. Clin Endocrinol (Oxf). 2016;85:29–36.CrossRefPubMed Xue S, Chen H, Lv C, et al. Preoperative diagnosis and prognosis in 40 parathyroid carcinoma patients. Clin Endocrinol (Oxf). 2016;85:29–36.CrossRefPubMed
11.
go back to reference Villar-del-Moral J, Jimenez-Garcia A, Salvador-Egea P, et al. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014;156:1132–44.CrossRefPubMed Villar-del-Moral J, Jimenez-Garcia A, Salvador-Egea P, et al. Prognostic factors and staging systems in parathyroid cancer: a multicenter cohort study. Surgery. 2014;156:1132–44.CrossRefPubMed
12.
go back to reference In H, Bilimoria KY, Stewart AK, et al. Cancer recurrence: an important but missing variable in national cancer registries. Ann Surg Oncol. 2014;21:1520–9.CrossRefPubMed In H, Bilimoria KY, Stewart AK, et al. Cancer recurrence: an important but missing variable in national cancer registries. Ann Surg Oncol. 2014;21:1520–9.CrossRefPubMed
13.
go back to reference Christakis I, Bussaidy N, Clarke C, et al. Differentiating atypical parathyroid neoplasm from parathyroid cancer. Ann Surg Oncol. 2016;23:2889–97.CrossRefPubMed Christakis I, Bussaidy N, Clarke C, et al. Differentiating atypical parathyroid neoplasm from parathyroid cancer. Ann Surg Oncol. 2016;23:2889–97.CrossRefPubMed
14.
go back to reference Talat N, Schulte KM. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010;17:2156–74.CrossRefPubMed Talat N, Schulte KM. Clinical presentation, staging and long-term evolution of parathyroid cancer. Ann Surg Oncol. 2010;17:2156–74.CrossRefPubMed
15.
go back to reference Shaha AR, Shah JP. Parathyroid carcinoma: a diagnostic and therapeutic challenge. Cancer. 1999;86:378–80.CrossRefPubMed Shaha AR, Shah JP. Parathyroid carcinoma: a diagnostic and therapeutic challenge. Cancer. 1999;86:378–80.CrossRefPubMed
Metadata
Title
Risk of Distant Metastasis in Parathyroid Carcinoma and Its Effect on Survival: A Retrospective Review from a High-Volume Center
Authors
Elliot A. Asare, MD, MS
Angelica Silva-Figueroa, MD
Kenneth R. Hess, PhD
Naifa Busaidy, MD
Paul H. Graham, MD
Elizabeth G. Grubbs, MD
Jeffrey E. Lee, MD
Michelle D. Williams, MD
Nancy D. Perrier, MD
Publication date
01-10-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 11/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07451-3

Other articles of this Issue 11/2019

Annals of Surgical Oncology 11/2019 Go to the issue